The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a

Biochemical Journal

Volumn 443, Issue 1, 2012, Pages 57-64

  Cameron, Amy R ^a   Wallace, Katherine ^a   Logie, Lisa ^a   Prescott, Alan R ^b   Unterman, Terry G ^c,d   Harthill, Jean ^a   Rena, Graham ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF ILLINOIS   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Clioquinol; Forkhead box O1a (FOXO1a); Insulin; Type 2 diabetes; Zinc

Indexed keywords

8 QUINOLINOL DERIVATIVE; ALLOXAN; BROXALDINE; CLIOQUINOL; DITHIZONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; QUINALDINE; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHR; XANTHURENIC ACID; ZINC ION;

ANIMAL CELL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIABETOGENESIS; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION; GLUCONEOGENESIS; HUMAN; HUMAN CELL; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; CLIOQUINOL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; HEK293 CELLS; HUMANS; HYDROXYQUINOLINES; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; ZINC;

RATTUS;

EID: 84858307296     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20112124     Document Type: Article

References (51)

1. Selman, C., Lingard, S. A. I., Choudhury, A. I., Batterham, R. L., Claret, M., Clements, M., Ramadani, F., Okkenhaug, K., Schuster, E., Blanc, E. et al. (2008) Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 22, 807-818 (Pubitemid 351348133)
2. Ogg, S., Paradis, S., Gottlieb, S., Patterson, G. I., Lee, L., Tissenbaum, H. A. and Ruvkun, G. (1997) The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389, 994-999 (Pubitemid 27485694)
3. Lin, K., Dorman, J. B., Rodan, A. and Kenyon, C. (1997) daf-16: an HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 278, 1319-1322 (Pubitemid 27495748)
4. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853
5. Evans, J. M. M., Ogston, S. A., Emslie-Smith, A. and Morris, A. D. (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49, 930-936
6. Kuusisto, J., Koivisto, K., Mykkanen, L., Helkala, E.-L., Vanhanen, M., Hanninen, T., Kervinen, K., Kesaniemi, Y. A., Riekkinen, P. J. and Laakso, M. (1997) Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study. Br. Med. J. 315, 1045-1049 (Pubitemid 27458392)
7. Watson, G. S. and Craft, S. (2003) The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17, 27-45 (Pubitemid 36044347)
8. Hallschmid, M. and Schultes, B. (2009) Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 52, 2264-2269
9. van der Heide, L. P., Hoekman, M. F. M. and Smidt, M. P. (2004) The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem. J. 380, 297-309 (Pubitemid 38788101)
10. Biggs, W. H., Meisenhelder, J., Hunter, T., Cavenee, W. K. and Arden, K. C. (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. U.S.A. 96, 7421-7426 (Pubitemid 29299677)
11. Rena, G., Prescott, A. R., Guo, S. D., Cohen, P. and Unterman, T. G. (2001) Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochem. J. 354, 605-612 (Pubitemid 32269724)
12. Rena, G., Woods, Y. L., Prescott, A. R., Peggie, M., Unterman, T. G., Williams, M. R. and Cohen, P. (2002) Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J. 21, 2263-2271 (Pubitemid 34516785)
13. Rena, G., Bain, J., Elliott, M. and Cohen, P. (2004) D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 5, 60-65 (Pubitemid 38228529)
14. Jacobs, F. M. J., van der Heide, L. P., Wijchers, P. J. E. C., Burbach, J. P. H., Hoekman, M. F. M. and Smidt, M. P. (2003) FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J. Biol. Chem. 278, 35959-35967 (Pubitemid 37139914)
15. Cameron, A. R., Anil, S., Sutherland, E., Harthill, J. and Rena, G. (2010) Zinc-dependent effects of small molecules on the insulin-sensitive transcription factor FOXO1a and gluconeogenic genes. Metallomics 2, 195-203
16. Onuma, H., Vander Kooi, B. T., Boustead, J. N., Oeser, J. K. and O'Brien, R. M. (2006) Correlation between FOXO1a (FKHR) and FOXO3a (FKHRL1) binding and the inhibition of basal glucose-6-phosphatase catalytic subunit gene transcription by insulin. Mol. Endocrinol. 20, 2831-2847 (Pubitemid 44833539)
17. Vander Kooi, B. T., Streeper, R. S., Svitek, C. A., Oeser, J. K., Powell, D. R. and O'Brien, R. M. (2003) The three insulin response sequences in the glucose-6-phosphatase catalytic subunit gene promoter are functionally distinct. J. Biol. Chem. 278, 11782-11793 (Pubitemid 36800147)
18. Sutherland, C., O'Brien, R. M. and Granner, D. K. (1995) Phosphatidylinositol 3-kinase, but not P70/P85 ribosomal s6 protein-kinase, is required for the regulation of phosphoenolpyruvate carboxykinase (PEPCK) gene-expression by insulin: dissociation of signaling pathways for insulin and phorbol ester regulation of PEPCK gene expression. J. Biol.Chem. 270, 15501-15506
19. Patel, S., Lochhead, P., Rena, G. and Sutherland, C. (2001) Antagonistic effects of phorbol esters on insulin regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) but not glucose-6-phosphatase gene expression. Biochem. J. 359, 611-619 (Pubitemid 33063386)
20. Patel, S., Lipina, C. and Sutherland, C. (2003) Different mechanisms are used by insulin to repress three genes that contain homologous thymine-rich insulin response elements. FEBS Lett. 549, 72-76 (Pubitemid 36959847)
21. Mora, A., Lipina, C., Tronche, F., Sutherland, C. and Alessi, D. R. (2005) Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem. J. 385, 639-648 (Pubitemid 40208823)
22. Logie, L., Ruiz-Alcaraz, A. J., Keane, M., Woods, Y. L., Bain, J., Marquez, R., Alessi, D. R. and Sutherland, C. (2007) Characterisation of a protein kinase B inhibitor in vitro and in insulin treated liver cells. Diabetes 56, 2218-2227 (Pubitemid 47358228)
23. Samuel, V. T., Choi, C. S., Phillips, T. G., Romanelli, A. J., Geisler, J. G., Bhanot, S., McKay, R. M., Monia, B., Shutter, J. R., Lindberg, R.A et al. (2006) Targeting Foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55, 2042-2050 (Pubitemid 44509978)
24. Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D. R., Le Angelos Klotsas, J., Matika, R., Xiao, X., Heidenrich, K. A., Sajan, M. P. et al. (2006) FOXO1 regulates multiple metabolic pathways in the liver. J. Biol. Chem. 281, 10105-10117
25. Nakae, J., Biggs III, W. H., Kitamura, T., Cavenee, W. K., Wright, C. V. E., Arden, K. C. and Accili, D. (2002) Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet. 32, 245-253
26. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F. et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909 (Pubitemid 36398297)
27. Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y. et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676 (Pubitemid 32607332)
28. Wang, Y., Branicky, R., Stepanyan, Z., Carroll, M., Guimond, M.-P., Hihih, A., Hayes, S., McBride, K. and Hekimi, S. (2009) The anti- neurodegeneration drug clioquinol inhibits the aging associated protein CLK-1. J. Biol. Chem. 284, 314-323
29. Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P. and Dou, Q. P. (2005) Anticancer activity of the antibiotic clioquinol. Cancer Res. 65, 3389-3395
30. Ding, W. Q., Liu, B., Vaught, J. L., Yamauchi, H. and Lind, S. E. (2005) Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 67, 1636-1644
31. White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A. et al. (2006) Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281, 17670-17680 (Pubitemid 44035565)
32. Caragounis, A., Du, T., Filiz, G., Laughton, K. M., Volitakis, I., Sharples, R. A., Cherny, R. A., Masters, C. L., Drew, S. C., Hill, A. F. et al. (2007) Differential modulation of Alzheimer's disease amyloid β-peptide accumulation by diverse classes of metal ligands. Biochem. J. 407, 435-450 (Pubitemid 350058477)
33. Du, T., Filiz, G., Caragounis, A., Crouch, P. J. and White, A. R. (2008) Clioquinol promotes cancer cell toxicity through tumor necrosis factor α release from macrophages. J. Pharmacol. Exp. Ther. 324, 360-367 (Pubitemid 350294161)
34. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K. et al. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59, 43-55 (Pubitemid 351905863)
35. Tsubaki, T., Honma, Y. and Hoshi, M. (1971) Neurological syndrome associated with clioquinol. Lancet 297, 696-697
36. Kadota, I. (1950) Studies on experimental diabetes mellitus, as produced by organic reagents. J. Lab. Clin. Med. 35, 568-591
37. Kadota, I. and Abe, T. (1954) Chemical specificity of diabetogenic action of quinoline derivatives. J. Lab. Clin. Med. 43, 375-385
38. Root, M. A. and Chen, K. K. (1952) Experimental diabetes induced by 8-hydroxyquinoline. J. Pharmacol. Exp. Ther. 104, 404-411
39. Epand, R. M., Stafford, A. R., Tyers, M. and Nieboer, E. (1985) Mechanism of action of diabetogenic zinc-chelating agents. Mol. Pharmacol. 27, 366-374 (Pubitemid 15142335)
40. Priel, T., Aricha-Tamir, B. and Sekler, I. (2007) Clioquinol attenuates zinc-dependent β-cell death and the onset of insulitis and hyperglycemia associated with experimental type I diabetes in mice. Eur. J. Pharmacol. 565, 232-239 (Pubitemid 46782768)
41. Rena, G., Guo, S. D., Cichy, S. C., Unterman, T. G. and Cohen, P. (1999) Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J. Biol. Chem. 274, 17179-17183
42. Rena, G., Woods, Y. L., Prescott, A. R., Peggie, M., Unterman, T. G., Williams, M. R. and Cohen, P. (2002) Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J. 21, 2263-2271 (Pubitemid 34516785)
43. Anton, S., Melville, L. and Rena, G. (2007) Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulin. Cell. Signalling 19, 378-383 (Pubitemid 44969987)
44. Cameron, A. R., Anton, S., Melville, L., Houston, N. P., Dayal, S., McDougall, G. J., Stewart, D. and Rena, G. (2008) Black tea polyphenols mimic insulin/IGF-1 signalling to the longevity factor FOXO1a. Aging Cell 7, 69-77
45. Green, C. J., Goransson, O., Kular, G. S., Leslie, N. R., Gray, A., Alessi, D. R., Sakamoto, K. and Hundal, H. S. (2008) Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J. Biol. Chem. 283, 27653-27667
46. Haase, H. and Maret, W. (2005) Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. Biometals 18, 333-338 (Pubitemid 41298017)
47. Resnick, R. A. and Cecil, H. (1956) The copper complex of alloxanic acid. Arch. Biochem. Biophys. 61, 179-185
48. Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W. H., Wright, C. V. E., White, M. F., Arden, K. C. and Accili, D. (2002) The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic β cell growth. J. Clin. Invest. 110, 1839-1847 (Pubitemid 36076491)
49. McLoughlin, T. J., Smith, S. M., DeLong, A. D., Wang, H., Unterman, T. G. and Esser, K. A. (2009) FoxO1 induces apoptosis in skeletal myotubes in a DNA-binding-dependent manner. Am. J. Physiol. Cell Physiol. 297, C548-C555
50. Lazaris, J. A. and Babelskyi, F. J. (1979) Preventive effect of diethyldithiocarbamate on experimental diabetes produced by dithisone and 8-oxychinoline. Endocrinol. Exp. 13, 39-51 (Pubitemid 9188999)
51. Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R. and de la Monte, S. M. (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimer's Dis. 9, 13-33